Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
90Y and 111In have been attached to chimeric monoclonal antibody L6 with a bifunctional chelating agent (DOTA-peptide isothiocyanate). The bifunctional chelating agent was prelabeled with either radiometal and then conjugated to the antibody. Studies in human patients showed excellent 111In single-photon emission computed tomography images of breast cancer lesions 24 h after injection.
D000818:Animals; D018033:Antibodies, Bispecific / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000276:immunology / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000737:chemistry* / Q000276:immunology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000276:immunology / Q000532:radiotherapy*; D016503:Drug Delivery Systems; D005260:Female; D006571:Heterocyclic Compounds; D006573:Heterocyclic Compounds, 1-Ring; D006801:Humans; D007205:Indium Radioisotopes; D007553:Isotope Labeling; D051379:Mice; D008819:Mice, Nude; D016499:Radioimmunotherapy; D015899:Tomography, Emission-Computed, Single-Photon; D015021:Yttrium Radioisotopes
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D006571:Heterocyclic Compounds; D006573:Heterocyclic Compounds, 1-Ring; D007205:Indium Radioisotopes; D015021:Yttrium Radioisotopes; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid